Genetic basis of pancreatic cancer

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 16, Issue 3, 2002, Pages 421-433

  Schmid, Roland M ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

AKT2; BRCA2; Cell cycle; INK4a; K Ras; LKB1 STK11; Mismatch repair; Oncogene; p53; Pancreatic cancer; Progression model; SMAD4; Tumour suppressor gene

Indexed keywords

PROTEIN P53; SMAD4 PROTEIN; BRCA2 PROTEIN; PROTEIN KINASE B BETA; PROTEIN KINASE LKB1; PROTEIN P14ARF; PROTEIN P16INK4A; TELOMERASE;

CANCER CELL; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; GENE ACTIVATION; GENE DUPLICATION; GENE LOCUS; GENE MUTATION; GENETIC SUSCEPTIBILITY; GERM LINE; HUMAN; METASTASIS; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS CELL; PRECANCER; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; CANCER GENETICS; CANCER INVASION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; GENE INACTIVATION; GENOMIC INSTABILITY; MISMATCH REPAIR; GENETICS; PANCREAS TUMOR;

HUMANS; PANCREATIC NEOPLASMS;

EID: 0036596511     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0316     Document Type: Article

References (100)

1. Rozenblum E Schutte M Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma Cancer Research 57 1997 1731-1734
2. Lavoie J N L'Allemain G Brunet A et al. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway Journal of Biological Chemistry 271 1996 20608-20616
3. Kerkhoff E Rapp U R Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1 Molecular and Cellular Biology 17 1997 2576-2586
4. Almoguera C Shibata D Forrester K Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes Cell 53 1988 549-554
5. Korc M Chandrasekar B Yamanaka Y et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha Journal of Clinical Investigation 90 1992 1352-1360
6. Gansauge S Gansauge F Ramadani M et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis Cancer Research 57 1997 1634-1637
7. Schutte M Hruban R H Geradts J et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Research 57 1997 3126-3130
8. Sherr C J Cancer cell cycles Science 274 1996 1672-1677
9. Sherr C J Roberts J M CDK inhibitors: positive and negative regulators of G1-phase progression Genes & Development 13 1999 1501-1512
10. Serrano M Hannon G J Beach D A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 366 1993 704-707
11. Hannon G J Beach D p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest Nature 371 1994 257-261
12. Caldas C Hahn S A da Costa L T et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nature Genetics 8 1994 27-32
13. Naumann M Savitskaia N Eilert C et al. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumours Gastroenterology 110 1996 1215-1224
14. Pomerantz J Schreiber-Agus N Liegeois N J et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 92 1998 713-723
15. Livingstone L R White A Sprouse J et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 Cell 70 1992 923-935
16. Serrano M Lin A W McCurrach M E et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a Cell 88 1997 593-602
17. Taylor W R Stark G R Regulation of the G2/M transition by p53 Oncogene 20 2001 1803-1815
18. Knudson A G Antioncogenes and human cancer Proceedings of the National Academy of Sciences of the USA 90 1993 10914-10921
19. Kinzler K Vogelstein B Lessons from hereditary colorectal cancer Cell 87 1996 159-170
20. Malumbres M Pellicer A Ras pathways to cell cycle control and cell transformation Frontiers in Bioscience 3 1998 887-912
21. Caldas C Kern S E K-ras mutation and pancreatic adenocarcinoma International Journal of Pancreatology 18 1995 1-6
22. Shirasawa S Furuse M Yokoyama N Sasazuki T Altered growth of human colon cancer cell lines disrupted at activated K-ras Science 260 1993 85-86
23. Quaife C J Pinkert C A Ornitz D M et al. Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice Cell 48 1987 1023-1034
24. Wagner M Greten F R Weber C K et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease Genes & Development 15 2001 286-293
25. Johnson L Mercer K Greenbaum D et al. Somatic activation of the k-ras oncogene causes early onset lung cancer in mice Nature 11 2001 2468-2481
26. Zhang, Z, Wang, Y, Vilkis, H, G, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice, Nature Genetics, 2001 29 25-33
27. Vogelstein B Fearon E R Hamilton S R et al. Genetic alterations during colorectal-tumor development New England Journal of Medicine 319 1988 525-532
28. Tada M Omata M Kawai S et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma Cancer Research 53 1993 2472-2474
29. Yanagisawa A Ohtake K Ohashi K et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation Cancer Research 53 1993 953-956
30. Tada M Ohashi M Shiratori Y et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease Gastroenterology 110 1996 227-231
31. Moskaluk C A Hruban R H Kern S E p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma Cancer Research 57 1997 2140-2143
32. Serrano M Lee H Chin L et al. Role of the INK4a locus in tumour suppression and cell mortality Cell 85 1996 27-37
33. Kamijo T Zindy F Roussel M F et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF Cell 91 1997 649-659
34. Sharpless N E Bardeesy N Lee K H et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis Nature 413 2001 86-91
35. Krimpenfort P Quon K C Mooi W J et al. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice Nature 413 2001 83-86
36. Gruis N A van der Velden P A Sandkuijl L A et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds Nature Genetics 10 1995 351-353
37. Goldstein A M Fraser M C Schuewing J P Increased risk of pancreatic cancer in melanoma-prone kindreds with p161NK4 mutations New England Journal of Medicine 333 1995 970-974
38. Whelam A J Bartsch D Goodfellow P J Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene New England Journal of Medicine 333 1995 975-977
39. Lynch H T Fitzsimmons M L Smyrk T C et al. Familial pancreatic cancer: clinicopathologic study of 18 nuclear families American Journal of Gastroenterology 85 1990 54-60
40. Randerson-Moor J A Harlan M William S A germline deletion of p14(ARF) but not CDKNZA in a melanoma-neural system tumour syndrome family Human Molecular Genetics 10 2001 55-62
41. Levine A J p53, the cellular gatekeeper for growth and division Cell 88 1997 323-331
42. Barton C M Staddon S L Hughes C M et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer British Journal of Cancer 64 1991 1076-1082
43. Redston M S Caldas C Seymour A B et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions Cancer Research 54 1998 3025-3033
44. Strong L C Stine M Norsted T L Cancer in survivors of childhood soft tissue sarcoma and their relatives Journal of the National Cancer Institute 79 1987 1213-1220
45. Li F P Fraumeni J F Jr Mulvihill J J et al. A cancer family syndrome in twenty-four kindreds Cancer Research 48 1988 5358-5362
46. Wrana J L Regulation of Smad activity Cell 100 2000 189-192
47. Hahn S A Schutte M Hoque A T et al. DPC4 a candidate tumor suppressor gene at human chromosome 18q21·1 Science 271 1996 350-353
48. Kretzschmar M Doody J Timokhina I Massague J A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras Genes & Development 13 1999 804-816
49. Scharte-Waldhoff I Volpert O V Bouck N P et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis Proceedings of the National Academy of Sciences of the USA 97 2000 9624-9629
50. Tascilar M Skinner H G Rosty C et al. The Smad4 protein and prognosis of pancreatic ductal adenocarcinoma Clinical Cancer Research 7 2001 4115-4121
51. Watson P Lynch H AT Extracolonic cancer in hereditary nonpolyposis colorectal cancer Cancer 71 1993 677-685
52. Aarnio M Mecklin J P Aaltonen L A et al. Life-time risk of different cancers in hereditary nonpolyposis colorectal cancer (HNPCC) syndrome International Journal of Cancer 64 1995 430-433
53. Ghimenti C Tannergard P Wahlberg S et al. Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours British Journal of Cancer 80 1999 11-16
54. Kondo E Furukawa T Yoshinaga K et al. Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability International Journal of Oncology 17 2000 535-541
55. Pantel K J Yu V P Lee H et al. Involvement of Brca2 in DNA repair Molecular Cell 1 1998 347-357
56. Marmorstein L Y Kinev A V Chan G KT et al. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression Cell 104 2001 247-257
57. Lancaster J M Wooster R Mangion J et al. BRCA2 mutations in primary breast and ovarian cancers Nature Genetics 13 1996 238-240
58. Goggins M Schutte M Lu J et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic and biliary adenocarcinomas Cancer Research 58 1999 5360-5364
59. Ozcelik H Schmocker B Di Nocala N et al. Germline BRCA2 6174deIT mutations in Ashkenazi Jewish pancreatic cancer patients Nature Genetics 16 1997 17-18
60. Bowlby L S Pancreatic carcinoma in an adolescent male with Peutz-Jeghers syndrome Human Pathology 17 1986 97-99
61. Giardiello F M Welsh S B Hamilton S R et al. Increased risk of cancer in the Peutz-Jeghers syndrome New England Journal of Medicine 316 1987 1511-1514
62. Spigelman A D Murday V Phillips R K Cancer and the Peutz-Jeghers syndrome Gut 30 1989 1588-1590
63. Giardiello F M Brensinger J D Tersmette A C et al. Very high risk of cancer in familial Peutz-Jeghers Syndrome Gastroenterology 119 2000 1447-1453
64. Sato N Rosty C Jansen M et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms on the pancreas American Journal of Pathology 159 2001 2017-2022
65. Franke T F Yang S I Chan T O et al. The protein kinase encoded by the Akt Proto-Oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase Cell 81 1995 727-736
66. Friess H Berberat M Schilling M et al. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors Journal of Molecular Medicine 74 1996 35-42
67. Cheng J Q Ruggeri B Klein W M et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proceedings of the National Academy of Sciences of the USA 93 1996 3636-3641
68. Miwa W Yasuda J Murakami Y et al. Isolation of DNA sequences amplified at chromosome 19q13·1-q13·2 including the AKT2 locus in human pancreatic cancer Biochemical and Biophysical Research Communications 225 1996 968-974
69. Ruggeri B A Huang L Wood M et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinoma Molecular Carcinogenesis 21 1988 81-86
70. Bodnar A G Ouellette M Frolkis M et al. Extension of life-span by introduction of telomerase into normal human cells Science 279 1998 349-352
71. Hahn W C Counter C M Lundberg A S et al. Creation of human tumour cells with defined genetic elements Nature 400 1999 464-468
72. Hiyama E Kodama T Shinbara K et al. Telomerase activity is detected in pancreatic cancer but not in benign tumours Cancer Research 57 1997 326-331
73. Suehara N Mizumoto K Muta T et al. Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states Clinical Cancer Research 3 1997 993-998
74. Longegger D S Shinozuka H Dekker A Focal acinar cell dysplasia in human pancreas Cancer 45 1980 534-540
75. Klöppel G Pathology of nonendocrine pancreatic tumours 1993 Raven Press New York p. 871-898
76. Pour P M Weide L Liu G et al. Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of Langerhans American Journal of Pathology 150 1997 2167-2180
77. Willentz R E Geradts J Maynard R et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression Cancer Research 58 1998 4740-4744
78. Hruban R H Wilentz R E Goggins M et al. Pathology of incipient pancreatic cancer Annals of Oncology 10 1999 S9-S11
79. Hruban R H Wilentz R E Kern S E Genetic progression in the pancreatic ducts American Journal of Pathology 156 2000 1821-1825
80. Wilentz R E Iacobuzio-Donahue C A Argani P et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression Cancer Research 60 2000 2002-2006
81. Hruban R H Adsay N V Albores-Saavedra J et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions American Journal of Surgery and Pathology 25 2001 579-586
82. Kern S Hruban R Hollingsworth M A et al. A white paper: the product of a pancreas cancer think tank Cancer Research 61 2001 4923-4932
83. Sommers S C Murphy S A Warren S Pancreatic duct hyperplasia and cancer Gastroenterology 27 1954 629-640
84. Cubilla A L Fitzgerald P J Morphological lesions associated with human primary invasive nonendocrine pancreatic cancer Cancer Research 36 1976 2690-2698
85. Furukawa T Chiba R Kobari M et al. Varying grades of epithelial atypia in the pancreatic ducts of humans: classification based on morphometry and multivariate analysis and correlated with positive reactions of carcinoembryonic antigen Archives of Pathology & Laboratory Medicine 118 1994 227-234
86. Kozuka S Sassa R Taki T et al. Relation of pancreatic duct hyperplasia to carcinoma Cancer 43 1979 1418-1428
87. Klöppel G Bommer G Rückert K Seifert G Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis Virchows Archiv 387 1980 221-233
88. DiGuiseppe J A Hruban R H Offerhaus G JA et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma American Journal of Pathology 144 1994 889-895
89. Yamano M Fujii H Takagaki T et al. Genetic progression and divergence in pancreatic carcinoma American Journal of Pathology 156 2000 2123-2133
90. Day J D DiGuiseppe J A Yeo C J et al. Immunhistochemical evaluation of HER-2/neu oncogene expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms Human Pathology 27 1996 119-124
91. DiGuiseppe J A Hruban R H Goodman S N et al. Overexpression of p53 protein in adenocarcinoma of the pancreas American Journal of Clinical Pathology 101 1994 684-688
92. Lüttges J Galehdari H Bröcker V et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis American Journal of Pathology 158 2001 1677-1683
93. Brat D J Lillemoe K D Yeo C J et al. Progression of pancreatic intraductal neoplasias (high-grade PanIN) to infiltrating adenocarcinoma of the pancreas American Journal of Surgical Pathology 22 1998 163-169
94. Brockie E Anand A Albores-Saavedra J Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma Annals of Diagnosis and Pathology 2 1998 286-292
95. Lüttges J Schlehe B Menke M AOH et al. The K-ras mutation pattern in pancreatic ductal adenocarcinoma is usually identical to that in associated normal, hyperplastic and metaplastic duct epithelium Cancer 85 1999 1703-1710
96. Lüttges J Diederichs A Menke M AOH et al. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53 Cancer 88 2000 2495-2504
97. Biankin A V Kench J G Morey A L et al. Overexpression of p21WAF1/CIP1 is an early event in the development of pancreatic intraepithelial neoplasia Cancer Research 61 2001 8830-8837
98. Apple S K Hecht J R Lewin D N et al. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence of multistep carcinogenesis Human Pathology 30 1999 123-129
99. Boschman C R Stryker S Reddy J K Sambasiva Rao M Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas American Journal of Pathology 145 1994 1291-1295
100. Heimöller E Dietmaier W Zirngibl H et al. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma American Journal of Pathology 157 2000 83-92